Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01873352 · ClinicalTrials.gov registry record · Phase 3
Renal Artery Denervation In Addition to Catheter Ablation To Eliminate Atrial Fibrillation
A Phase 3 study, sponsored by Meshalkin Research Institute of Pathology of Circulation.
- Completed
- Registry status
- Phase 3
- Development phase
- 302
- Enrollment target
NCT01873352 is a Phase 3 study that has completed, run by Meshalkin Research Institute of Pathology of Circulation. The registered enrollment target is 302 participants.
The verdict
NCT01873352, a Phase 3 study, has completed, sponsored by Meshalkin Research Institute of Pathology of Circulation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 302 participants
- Enrollment target
Study Summary
The objective of this trial is to determine the role of renal sympathetic denervation in the prevention of atrial fibrillation (AF) recurrence in patients with hypertension for whom a catheter-based AF ablation procedure is planned. Patients will be randomized to either AF catheter ablation (usual therapy) or AF catheter ablation plus renal sympathetic denervation.
Interventions
- PROCEDURE catheter ablation
- PROCEDURE renal sympathetic denervation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 302 participants |
| Start Date | 2013-06-20 |
| Est. Completion | 2019-03-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01873352
The ClinicalTrials.gov registry entry for NCT01873352 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 302 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Meshalkin Research Institute of Pathology of Circulation, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which catheter ablation is the first listed.
NCT01873352 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01873352 about?
NCT01873352 is a clinical study titled "Renal Artery Denervation In Addition to Catheter Ablation To Eliminate Atrial Fibrillation". The objective of this trial is to determine the role of renal sympathetic denervation in the prevention of atrial fibrillation (AF) recurrence in patients with hypertension for whom a catheter-based AF ablation procedure is planned. Patients will be randomized to either AF catheter ablation (usual t...
What is the current status of trial NCT01873352?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 302 participants. The study started on 2013-06-20. Estimated completion is 2019-03-01.
What interventions are being tested in trial NCT01873352?
The interventions under investigation include: catheter ablation (PROCEDURE), renal sympathetic denervation (PROCEDURE).
Who is sponsoring clinical trial NCT01873352?
This trial is sponsored by Meshalkin Research Institute of Pathology of Circulation, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.